Reuters logo
BRIEF-Mast Therapeutics announces clinical study of AIR001 for the treatment of chronic infection in cystic fibrosis patients
March 6, 2017 / 1:22 PM / in 8 months

BRIEF-Mast Therapeutics announces clinical study of AIR001 for the treatment of chronic infection in cystic fibrosis patients

March 6 (Reuters) - Mast Therapeutics Inc

* Mast Therapeutics announces clinical study of AIR001 for the treatment of chronic infection in cystic fibrosis patients

* Mast Therapeutics - unit Aires Pharmaceuticals entered into agreement related to phase 1/2 open-label safety and proof of concept clinical trial of AIR001

* Mast Therapeutics Inc - study is being conducted by University Of Pittsburgh and University Of Pittsburgh Medical Center

* Mast Therapeutics Inc- subsidiary will provide study drug and nebulizers for study, but no direct financial support

* Mast Therapeutics Inc - under agreement company has rights to use de-identified data and study results for potential regulatory submissions Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below